Drug Topics

SEPTEMBER 13, 2024

Gilead said data from the study will support global regulatory filings that the company plans to begin by the end of the year.

211

211

Pharmacy Is Right For Me

SEPTEMBER 13, 2024

Written by: Toni Mikhael, PharmD, Touro College of Pharmacy Class of 2024. PGY-1 Pharmacy Resident, WellSpan Ephrata Community Hospital, Ephrata, PA Edited by: Anastasiya Shor, PharmD, BCPS Pharmacy school is a challenging but rewarding journey. As students embark on this demanding path, it becomes crucial to equip themselves with a toolkit for success.

Patient Care 130

Patient Care Medical Schools Hospitals 130

STAT

SEPTEMBER 13, 2024

A close contact of the person in Missouri who had an unexplained H5N1 bird flu infection last month was also sick around the same time, but was not tested for influenza, the Centers for Disease Control and Prevention reported on Friday.  The CDC revealed the previously undisclosed information in FluView , its weekly report on influenza activity.

145

145

Drug Topics

SEPTEMBER 13, 2024

Over 30 million American adults experience some hearing loss, yet only one-fifth benefit from hearing aids; the FDA’s approval will expand access to the technology for the patient population.

FDA 112

FDA 112

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

SEPTEMBER 13, 2024

For more cancer coverage, sign up for STAT’s pop-up newsletter focused on this weekend’s European Society for Medical Oncology conference, one of the biggest oncology meetings of the year. Details here. When Rachel Guberman found out she had brain cancer, she did so much reading and Googling about the disease that she joked she had reached the end of the internet.

Chemotherapy 145

Chemotherapy 145

Pharmacy Times

SEPTEMBER 13, 2024

These results build off the PURPOSE 1 trial, contributing to the wealth of evidence surrounding lenacapavir’s positive effects in patients with HIV.

139

139

Pharmacy Times

SEPTEMBER 13, 2024

In the absence of a common treatment for long COVID, researchers from around the world documented the best currently available therapies.

Documentation 145

Documentation 145

Fierce Healthcare

SEPTEMBER 13, 2024

UTHealth Houston unveiled a partnership with OpenAI on Friday to build and deploy algorithms for use in medical training and at the patient’s bedside. | UTHealth Houston, an academic medical center in Texas, is partnering with OpenAI to give clinicians, faculty and students access to ChatGPT tools to build custom, HIPAA-compliant AI solutions.

HIPAA 125

HIPAA 125

Pharmacy Times

SEPTEMBER 13, 2024

The Hearing Aid Feature can be customized to the user’s needs by amplifying sounds for individuals 18 years or older who have perceived mild to moderate hearing impairments.

FDA 122

FDA 122

Fierce Pharma

SEPTEMBER 13, 2024

It’s better late than never for an FDA approval for the first subcutaneous PD-L1 inhibitor, which was doled out to Roche’s Tecentriq Hybreza after manufacturing delays derailed the company's initia | The under-the-skin formulation trims administration time down to seven minutes compared to the 30 to 60 minutes needed for intravenous Tecentriq.

FDA 125

FDA 125

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

STAT

SEPTEMBER 13, 2024

For years, health insurers battled to gain market share in the lucrative privatized Medicare program. Now, the opposite is true. Some of the companies say they designed their 2025 plans with an eye toward ditching members.  Health insurance has always been cyclical — companies go all-in on certain business lines when they’re profitable and get out when they’re not — but next year will mark a particularly drastic turning point for Medicare Advantage , the form of

Insurance 130

Insurance 130

Pharmacy Times

SEPTEMBER 13, 2024

The approval marks the first and only twice yearly, health care professional-administrated injection for both forms of multiple sclerosis (MS).

FDA 131

FDA 131

Fierce Pharma

SEPTEMBER 13, 2024

When Roche's Genentech gained approval for Ocrevus in 2017, the first-in- | The day after Roche gained an FDA approval for its subcutaneous version of cancer drug Tecentriq, the company also scored with a U.S. nod for its under-the-skin formulation of mega-blockbuster multiple sclerosis drug Ocrevus. The approval gives patients a more convenient injected way to receive Ocrevus as opposed to the infused formulation.

FDA 120

FDA 120

Pharmacy Times

SEPTEMBER 13, 2024

Data show the value of the pharmacist is clear for patients with type 2 diabetes, as their role can have a significant impact on reductions in hemoglobin A1c.

123

123

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Fierce Pharma

SEPTEMBER 13, 2024

Daiichi Sankyo and AstraZeneca are padding the case for their antibody-drug conjugate Enhertu with new data demonstrating the medicine’s worth in patients whose cancer has spread to the b | To bolster Enhertu's case in HER2-positive breast cancer, AstraZeneca and Daiichi Sankyo have rolled out positive data for the antibody-drug conjugate in patients who have brain metastases.

120

120

STAT

SEPTEMBER 13, 2024

I first met Jane (not her real name, of course) on a Friday afternoon in our clinic. She was referred for further evaluation of her chest pain, which, in the context of her family history of early-onset heart attacks and her morbid obesity, understandably concerned her primary care doctor. In the exam room, we dissected her symptoms and decided we’d investigate them further with a stress test.

Compounding 125

Compounding 125

Fierce Healthcare

SEPTEMBER 13, 2024

James Ross, president and CEO of West Tennessee Healthcare, died Thursday morning, according to an announcement from the health system on social media. | The nurse-executive had been with the seven-hospital nonprofit for nearly four decades and was a prominent member of the Jackson, Tennessee, community.

Hospitals 110

Hospitals 110

STAT

SEPTEMBER 13, 2024

Swiss pharma giant Roche won approval from the Food and Drug Administration on Friday for an injectable version of its blockbuster multiple sclerosis therapy Ocrevus, cutting down the time needed to treat patients and potentially staving off growing competition. The approval was driven by the results of a late-stage trial , OCARINA II, in which the company showed that delivering Ocrevus as a 10-minute injection beneath the skin worked as well as the current approach, an hours-long intravenous in

FDA 120

FDA 120

Fierce Pharma

SEPTEMBER 13, 2024

In a rough day for PARP inhibitors in ovarian cancer, GSK’s Zejula didn’t deliver a life extension benefit in the final analysis of a phase 3 trial. | In a rough day for PARP inhibitors in ovarian cancer, GSK’s Zejula didn’t deliver a life extension benefit in the final analysis of a phase 3 trial. Another study showed that Pharma&’s attempt to enhance its Rubraca with Bristol Myers Squibb’s Opdivo seriously backfired.

113

113

Drug Topics

SEPTEMBER 13, 2024

Researchers analyzed the outcomes of positive airway pressure therapy for Medicare beneficiaries with obstructive sleep apnea.

112

112

STAT

SEPTEMBER 13, 2024

This is the online edition of ESMO in 30 Seconds, a pop-up newsletter from the European Society for Medical Oncology’s annual meeting in Barcelona, Spain. Sign up for the remaining editions here. One of the big presentations of this year’s ESMO (at least in our view) comes tomorrow morning bright and early. David Spigel of Sarah Cannon Research Institute in Nashville will unveil results from the GALAXIES Lung-201 study of an anti-TIGIT therapy from iTeos Therapeutics and GSK in non

112

112

Drug Topics

SEPTEMBER 13, 2024

During an interview, Joseph Shields of TransparencyRx discusses the PBM legislation that is expected to move forward in Congress in the next few months.

98

98

pharmaphorum

SEPTEMBER 13, 2024

It's known that excessive use of earbuds at high volumes can cause hearing loss, so somewhat ironic that the FDA has just authorised software that can turn Apple AirPods into hearing aids.The green light is for Hearing Aid Feature (HAF), an app compatible with Apple's AirPods Pro earbuds that amplifies sounds and can be used for people aged 18 and over with perceived mild to moderate hearing impairment.

FDA 112

FDA 112

Drug Topics

SEPTEMBER 13, 2024

Researchers conducted a meta-analysis detailing previous patient outcomes in response to visual art therapy interventions.

112

112

Fierce Pharma

SEPTEMBER 13, 2024

Even for Merck’s oncology powerhouse Keytruda, the emerging role of immunotherapies in gynecological cancer treatment represents a bit of a mixed bag. | The company unveiled new data from its KEYNOTE-A18 study in late stage cervical cancer and its failed KEYNOTE-B21 trial testing Keytruda as an adjuvant therapy in newly diagnosed endometrial cancer.

106

106

STAT

SEPTEMBER 13, 2024

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Good morning, and congratulations on making it through another week. What’s been helping me get through this week is this baby hippo in Thailand called Moo Deng (which apparently translates to Bouncy Pig). She is very likely the cutest and most relatable animal I’ve ever seen.

113

113

Pharmacy Times

SEPTEMBER 13, 2024

Exposure to high cholesterol levels is a significant risk factor for atherosclerosis cardiovascular disease.

132

132

pharmaphorum

SEPTEMBER 13, 2024

Eli Lilly has added $1 billion to its investment plan for a new manufacturing facility in Ireland that will be used to produce its Alzheimer's therapy donanemab.The facility at a business park in Raheen, Limerick, was first announced in 2022 and this is the second time that Lilly has opted to double its investment in the site, taking the total above $2 billion and reinforcing the company's close ties to Ireland's pharma manufacturing sector.

105

105

STAT

SEPTEMBER 13, 2024

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others.  That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week.

105

105

The Checkup by Singlecare

SEPTEMBER 13, 2024

Stelara (ustekinumab) is an injectable drug approved by the Food and Drug Administration (FDA) for the treatment of autoimmune conditions, such as plaque psoriasis, active psoriatic arthritis, and inflammatory bowel diseases, including Crohn’s disease , and ulcerative colitis. There are no known food-drug interactions with Stelara. Still, it may cause digestive side effects, especially if you have an inflammatory bowel disease (IBD).

Vaccines 105

Vaccines Immunization Labelling Hospitals 105

Fierce Pharma

SEPTEMBER 13, 2024

As if a limited initial FDA approval was not bad enough, AstraZeneca’s Truqap has recorded a pivotal trial flop that could raise additional doubts around the first-in-class AKT inhibitor. | AstraZeneca is detailing Truqap's pivotal trial flop in triple-negative breast cancer, a result that could raise additional doubts around the first-in-class AKT inhibitor.

FDA 104

FDA 104

Fierce Healthcare

SEPTEMBER 13, 2024

Below is a roundup of payer-centric news headlines you may have missed during the month of September 2024. | This month, Humana faces consequences for prior auth delays, Congress members have introduced new No Surprises Act legislation targeting insurers and Aetna has been sued for denying gender-affirming facial reconstruction surgeries.

Insurance 102

Insurance 102

STAT

SEPTEMBER 13, 2024

BARCELONA, Spain — Adding a second immunotherapy from Bristol Myers Squibb to an existing checkpoint inhibitor and chemotherapy improved responses for certain patients with a type of lung cancer, steering the approach into a Phase 3 study.  The Phase 2 RELATIVITY-104 trial was another hurdle for BMS’ Opdualag, which is essentially a combination of the company’s powerhouse PD-1 inhibitor Opdivo and relatlimab, which targets another checkpoint called LAG-3.

Chemotherapy 117

Chemotherapy 117

Fierce Pharma

SEPTEMBER 13, 2024

ESMO: Novartis, Daiichi, Gilead, Astellas and AZ excel in analysis of clinical value added from new cancer approvals kdunleavy Fri, 09/13/2024 - 07:38

119

119